MiniMed Group(NASDAQ) MMED

MiniMed Group, Inc. makes tools to help people manage diabetes. Its devices track blood sugar and deliver insulin to the body. These products help patients and doctors control health more easily.

Tools for Better Health

• Continuous Glucose Monitors: Sensors that measure blood sugar; generated $431 million in net sales for the three months ended July 31, 2026.
• Insulin Pumps: Automated devices that deliver insulin; generated $144 million in net sales for the three months ended July 31, 2026.
• Consumables: Single-use items like infusion sets and reservoirs needed for pump systems; generated $261 million in net sales for the three months ended July 31, 2026.
• Smart MDI Systems: Integrated solutions including smart insulin pens and dosing software for patients who use manual injections.

Strategic Growth and Partnerships

• Completed a separation from Medtronic and began operating as a standalone public company on March 9, 2026.
• Launched the MiniMed Go smart insulin pen system in Europe in Feb. 2026 and in the U.S. in May 2026.
• Extended a partnership with Abbott Laboratories in June 2026 to integrate glucose-ketone sensors with smart dosing systems.
• Received CE Mark approval for the MiniMed Flex platform in Sept. 2026 to support European commercial launches.
• Submitted the MiniMed Fit patch pump to the U.S. Food and Drug Administration in Sept. 2026.

What Sets MiniMed Apart?

MiniMed provides every part of the insulin therapy ecosystem, including pumps, sensors, and dosing software. This integrated model allows the company to capture more revenue per user than competitors who only offer single components.

Financial Performance Highlights

• Net sales were $843 million for the three months ended July 31, 2026, up 16.6% year over year.
• International net sales hit $603 million for the three months ended July 31, 2026, up 18.1% year over year.
• Adjusted EBITDA was $83 million for the three months ended July 31, 2026, up from $50 million in the prior year.
• New pumps sold rose to 34,000 for the three months ended July 31, 2026, up from 32,000 in the prior year.

Evolution of the Business

MiniMed has transitioned from a division of Medtronic to an independent medical technology company focused on automated diabetes solutions. Its focus on integrated hardware and software platforms supports its growth in global healthcare markets.